Gastroenterology

Gastroenterology

Volume 121, Issue 1, July 2001, Pages 170-183
Gastroenterology

Liver, Pancreas, and Biliary Tract
Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse Liver

https://doi.org/10.1053/gast.2001.25542Get rights and content

Abstract

Background & Aims: Cholestasis is associated with retention of potentially toxic bile acids and alterations in hepatocellular transporter expression. Conversely, nontoxic ursodeoxycholic acid (UDCA) stimulates bile secretion and counteracts cholestasis. This study aimed to determine the effects of UDCA and cholic acid (CA) on the expression of hepatocellular transporters for bile acids (Ntcp, Bsep), organic anions (Oatp1, Mrp2), organic cations (Mdr1a/b), and phospholipids (Mdr2) in mouse liver. Methods: Bile flow/composition was analyzed in UDCA- or CA-fed mice. Transporter expression was studied by reverse-transcription polymerase chain reaction, Western blotting, and immunofluorescence microscopy. Results: UDCA had no effect on basolateral Ntcp and down-regulated Oatp1, whereas canalicular Bsep and Mrp2 were up-regulated. CA down-regulated basolateral Ntcp and Oatp1, whereas canalicular Bsep, Mrp2, and Mdr1a/b were up-regulated. Neither UDCA nor CA affected Mdr2 expression. Both UDCA and CA stimulated biliary bile acid and glutathione excretion, although only CA increased phospholipid and cholesterol excretion. Conclusions: Down-regulation of basolateral and up-regulation of canalicular transporters in response to CA may represent a defense mechanism, in an attempt to prevent hepatocellular accumulation of potentially toxic bile acids. The therapeutic effects of UDCA may be caused in part by stimulation of canalicular transporter expression in the absence of hepatocellular toxicity.

References (0)

Cited by (233)

  • Drug Transporters: Efflux

    2022, Comprehensive Pharmacology
  • Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis

    2019, Biochemical Pharmacology
    Citation Excerpt :

    Similarly to Bsep, Mrp2 gene transcription was enhanced by UDCA in LPS cholestatic rats (see Table 6); this may reflect, again, the capability of UDCA to counteract cytokine-mediated effects on Mrp2 transcription mechanisms, which is also JNK-dependent in nature [63,65]. In addition, the well characterized inductive effect that UDCA has per se on Mrp2 expression [60] may be another contributing factor. Surprisingly, an enhanced Mrp2 mRNA levels in the co-treated group did not lead to an improved expression of Mrp2 either at the protein level (see Table 4) or at a functional levels, as evaluated by assessing the biliary excretion of its exogenous substrate, BSP (see Fig. 2).

  • Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease

    2019, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    It is possible that elevated plasma Aβ in APP/PS1 mice27 may also alter renal transporter and metabolizing enzymes expression, which has not yet been studied. It is also very likely that given that plasma levels of bile acids and inflammatory mediators are also modified in AD, and they have been reported to affect the expression of peripheral transporters,11,26 the modified expression of the transporters observed could be a result of not only Aβ but also bile acids and inflammatory mediators. In summary, these studies have demonstrated that the renal expression of key drug transporters Mrp2, Oct2, and Oat3 is modestly, but significantly, increased in a mouse model of familial AD.

  • Animal models to study bile acid metabolism

    2019, Biochimica et Biophysica Acta - Molecular Basis of Disease
    Citation Excerpt :

    In wild type mice, expression of Cyp7a1, Cyp7b1, and the sinusoidal membrane bile acid uptake transporters Ntcp and Oatp1a1 are down-regulated by CA feeding [49,252], whereas expression of the canalicular membrane transporters Bsep, Mrp2, and Mdr1a/b is up-regulated [252]. Liver morphological changes induced by CA feeding includes disseminated hepatocyte necrosis, increased cell size, increased number of mitotic figures, and dilation of interlobular bile ducts [252]. Feeding CA (typically ~0.5%) to mice with genetic defects in bile acid biosynthetic enzymes or transporters is typically used to unmask susceptibilities to liver injury.

View all citing articles on Scopus
View full text